Old Web
English
Sign In
Acemap
>
authorDetail
>
John M. Goldman
John M. Goldman
Hammersmith Hospital
Imatinib
Internal medicine
Medicine
Myeloid leukemia
Immunology
3
Papers
442
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
2010
Blood
Timothy P. Hughes
Andreas Hochhaus
Susan Branford
Martin C. Müller
Jaspal Kaeda
Letizia Foroni
Brian J. Druker
François Guilhot
Richard A. Larson
Stephen G. O’Brien
Marc Rudoltz
Manisha Mone
Elisabeth Wehrle
Vijay Modur
John M. Goldman
Jerald P. Radich
Show All
Source
Cite
Save
Citations (404)
Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)
2008
Blood
Timothy P. Hughes
Andreas Hochhaus
Susan Branford
Martin C. Müller
Letizia Foroni
Brian J. Druker
François Guilhot
Richard A. Larson
Stephen G. O'Brien
Roger J. Waltzman
Manisha Mone
Elisabeth Wehrle
Jerald P. Radich
John M. Goldman
Show All
Source
Cite
Save
Citations (32)
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
2005
Nature Reviews Clinical Oncology
John M. Goldman
Show All
Source
Cite
Save
Citations (6)
1